| Name | Yankton Drug Co Inc |
|---|---|
| Organization Name | Yankton Drug Co Inc |
| Location | 109 W 3rd St, Yankton, South Dakota 57078 |
| Type | Pharmacy |
| Phone | (605) 665-7865 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Two new studies presented at the European Respiratory Society International Congress highlight the risks associated with using e-cigarettes, especially for those who also smoke conventional cigarettes.
A new approach of treating life-threatening snake bites responsible for around 100,000 deaths globally each year is being pioneered by an international research consortium led by University of Bristol scientists.
An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.
Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding, according to a study in the August 18 issue of JAMA.
Stem Cell Assurance, Inc. announced today that the Company will be focusing on four business development initiatives Lipo Rejuvenation Centers, Cellular Treatment Programs, Laboratory Science Investigations, and its Skincare Brand, Stem Cellutrition.
› Verified 6 days ago
| NPI Number | 1013022052 |
| Organization Name | YANKTON DRUG CO INC |
| Doing Business As | YANKTON REXALL DRUG |
| Type | Pharmacy |
| Address | 109 W 3rd St, Yankton, SD 57078 |
| Phone Number | 605-665-7865 |
News Archive
Two new studies presented at the European Respiratory Society International Congress highlight the risks associated with using e-cigarettes, especially for those who also smoke conventional cigarettes.
A new approach of treating life-threatening snake bites responsible for around 100,000 deaths globally each year is being pioneered by an international research consortium led by University of Bristol scientists.
An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.
Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding, according to a study in the August 18 issue of JAMA.
Stem Cell Assurance, Inc. announced today that the Company will be focusing on four business development initiatives Lipo Rejuvenation Centers, Cellular Treatment Programs, Laboratory Science Investigations, and its Skincare Brand, Stem Cellutrition.
› Verified 6 days ago
| NPI Number | 1346026796 |
| Organization Name | YANKTON DRUG CO INC |
| Type | Long Term Care Pharmacy |
| Address | 109 W 3rd St, Yankton, SD 57078 |
| Phone Number | 605-665-7866 |
News Archive
Two new studies presented at the European Respiratory Society International Congress highlight the risks associated with using e-cigarettes, especially for those who also smoke conventional cigarettes.
A new approach of treating life-threatening snake bites responsible for around 100,000 deaths globally each year is being pioneered by an international research consortium led by University of Bristol scientists.
An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.
Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding, according to a study in the August 18 issue of JAMA.
Stem Cell Assurance, Inc. announced today that the Company will be focusing on four business development initiatives Lipo Rejuvenation Centers, Cellular Treatment Programs, Laboratory Science Investigations, and its Skincare Brand, Stem Cellutrition.
› Verified 6 days ago
News Archive
Two new studies presented at the European Respiratory Society International Congress highlight the risks associated with using e-cigarettes, especially for those who also smoke conventional cigarettes.
A new approach of treating life-threatening snake bites responsible for around 100,000 deaths globally each year is being pioneered by an international research consortium led by University of Bristol scientists.
An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.
Among patients with active cancer and acute symptomatic venous thromboembolism (VTE; blood clots in the deep veins), the use of the low molecular-weight heparin tinzaparin daily for 6 months compared with warfarin did not significantly reduce recurrent VTE and was not associated with reductions in overall death or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding, according to a study in the August 18 issue of JAMA.
Stem Cell Assurance, Inc. announced today that the Company will be focusing on four business development initiatives Lipo Rejuvenation Centers, Cellular Treatment Programs, Laboratory Science Investigations, and its Skincare Brand, Stem Cellutrition.
› Verified 6 days ago
Wal-mart Pharmacy 10-1483 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3001 Broadway Ave, Yankton, South Dakota 57078 Phone: (605) 665-8197 | |
Hy-vee Pharmacy #1899 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2100 Broadway Ave, Yankton, South Dakota 57078 Phone: (605) 665-8261 | |
Yankton Medical Clinic Pharmacy Type: Pharmacy Location: 1104 W 8th St, Yankton, South Dakota 57078 Phone: (605) 665-2929 | |
Yankton Drug Co Inc Type: Pharmacy Location: 109 W 3rd St, Yankton, South Dakota 57078 Phone: (605) 665-7865 | |
Walgreens #9806 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2020 Broadway Ave, Yankton, South Dakota 57078 Phone: (605) 665-1124 |